US FDA Warns Intas To Assess Global Quality Following Plant’s Data Integrity Meltdown

 
• By Bowman Cox

Warning letter details extensive GMP and data integrity remediation expectations for Matoda plant and calls for the privately held generic drug manufacturer to immediately confront its corporate quality issues globally.

Microbial colony counting
the fda saw bacterial colony undercounting and much more • Source: Shutterstock

More from Manufacturing

More from Compliance